As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >


Pépinière Genopole Entreprises – 4, rue Pierre Fontaine – Genopole Campus 3
91058 EVRY Cedex – FRANCE
Phone: +33 1 60 87 89 80

Jean-Gabriel JUDDE: President & CSO
Site Web >

#R&D Services and Products

  • Oncology
  • Preclinical expertise
  • Predictive models
  • Biomarkers
  • Companion tests
  • New therapeutic targets
  • Patient-derived tumor xenografts

Field of Activity

XenTech is an innovative biotech company specialized in the preclinical evaluation of cancer drugs and the identification of biomarkers and therapeutic targets.


XenTech was founded in 2006 by researchers from the Institut Curie having over 15 years of experience in preclinical pharmacology in oncology. This spin-off company dedicated to biomarker discovery and preclinical evaluation of anticancer therapies is known worldwide for its expertise in the field of patient-derived tumor xenografts (PDX).
Located on the Genopole Campus, its experimental models are housed at the CERFE.


XenTech develops an innovative experimental platform based on one of the world’s largest collections of patient derived tumors xenografts (PDX). The collection is representative of the major types of cancer (breast, lung, colon, prostate) but also includes less common tumors (melanoma, ovarian cancer, renal cancer, pancreatic cancer, glioma, hepatoblastoma).
XenTech’s platform is of considerable value for translational research in oncology, notably for drug screening and the identification of biomarkers useful for precision oncology.
XenTech participates in the development of novel cancer therapies by offering its services, models and expertise in preclinical oncology to stakeholders in oncology research.


  • Partnership with the world’s biggest pharmaceutical companies involved in oncology.
  • Partnerships with major Cancer Centers.
  • Member of the ITCC-P4 consortium, a European IMI2 project to develop a platform for pediatric cancer models


  • Collaborative partnership with the pharmaceutical industry on drug response biomarkers and new therapeutic targets discovery programs.
  • Collaborative partnership with hospital structures to pursue development of the preclinical platform.
  • Research fee-for-service contracts with pharmaceutical companies, biotechs and academic groups for evaluating antitumor efficacy of their drug candidates.
  • Further Information

    Annual turnover: €3M
    32 staff members

    A unique panel of breast cancers preclinical models.
    World-renowned experimental platform and scientific expertise.

    An experimental platform and scientific expertise recognized worldwide.
    A network of partners and customers extended internationally.

Genopole’s Companies

#R&D Services and Products

In same field

Adlin Science - Genopole's Company

Adlin Science

ADLIN Science accompanies researchers in the management, analysis and valorization of multiomic data

Altar - entreprise génopolitaine


Altar is a specialist in the conception and operation of automated fluidic continuous culture systems for adaptive laboratory evolution and the development of microbial strains for industry.

Yubsis - Genopole's company


Yubsis provides Biological Science Information Solutions. Our platform is designed for research organizations willing to improve real-time teamwork, optimize performance and accelerate innovation

Whitelab Genomics - Genopole's Company

WhiteLab Genomics

Artificial intelligence to optimize and accelerate the development of gene therapies

Pymabs - Genopole's Company


R & D services in the field of transient expression of recombinant proteins in plants.

Polytheragene - Genopole's Company


Manufacture and sale of new high performance transfecting agents for gene therapy, high-throughput screening and biomanufacturing. Cosmetic and therapeutic molecules from plant biomass.

Phinc Development - Genopole's Company

PhinC Development

Drug development support to biotech and small pharma companies in early phases from preclinical studies to phase IIa trials.

New England Biolabs - Genopole's Company

New England Biolabs France

New England Biolabs is a private company manufacturing reagents for the life science industry particularly focused on products for genomic research.

LPS Biosciences - Genopole's company


LPS-BioSciences is specialized in bacterial endotoxins. It combines an exclusive proprietary technology for endotoxin production and characterization. and its acquired experience in the fields of vaccines, diagnostics, and the food industry.

Hybrigenics - Genopole's company

Hybrigenics Services

Hybrigenics Services offers high-quality services to i) discover novel protein interactions, ii) identify the targets of drug candidates and iii) select novel, synthetic single-domain antibodies against any antigen (nanobodies).

logo abcell Bio - Genopole's Companie


Abcell-bio is a laboratory specializing in the isolation of human hematopoietic stem cells and primary cells derived from perinatal tissue and cord blood.

View all >
With the support from